Last reviewed · How we verify

Nuron Biotech Inc. — Portfolio Competitive Intelligence Brief

Nuron Biotech Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NU100 NU100 phase 3 S1P1 receptor modulator S1P1 Multiple Sclerosis
rhIFN beta-1b rhIFN beta-1b phase 3 Interferon IFN-beta receptor Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Active Biotech AB · 1 shared drug class
  2. Archigen Biotech Limited · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. BioLineRx, Ltd. · 1 shared drug class
  6. Biogen · 1 shared drug class
  7. Bright Minds Biosciences Pty Ltd · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nuron Biotech Inc.:

Cite this brief

Drug Landscape (2026). Nuron Biotech Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nuron-biotech-inc. Accessed 2026-06-10.

Related